Metropolitan Life Insurance Company (MetLife)’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-7,891
| Closed | -$1.34M | – | 2262 |
|
|
2021
Q4 | $1.34M | Sell |
7,891
-61
| -0.8% | -$11.3K | 0.02% | 763 |
|
|
2021
Q3 | $1.5M | Sell |
7,952
-8,294
| -51% | -$1.56M | 0.02% | 677 |
|
|
2021
Q2 | $2.75M | Buy |
16,246
+7,855
| +94% | +$1.15M | 0.02% | 743 |
|
|
2021
Q1 | $1.18M | Sell |
8,391
-378
| -4% | -$56.9K | 0.02% | 830 |
|
|
2020
Q4 | $1.14M | Sell |
8,769
-171
| -2% | -$22.8K | 0.02% | 794 |
|
|
2020
Q3 | $1.3M | Sell |
8,940
-141
| -2% | -$20K | 0.02% | 602 |
|
|
2020
Q2 | $1.34M | Buy |
9,081
+2,348
| +35% | +$317K | 0.02% | 576 |
|
|
2020
Q1 | $733K | Sell |
6,733
-99
| -1% | -$11.4K | 0.02% | 835 |
|
|
2019
Q4 | $787K | Sell |
6,832
-118
| -2% | -$11.8K | 0.01% | 1046 |
|
|
2019
Q3 | $559K | Buy |
6,950
+535
| +8% | +$42.3K | 0.01% | 1217 |
|
|
2019
Q2 | $465K | Sell |
6,415
-142
| -2% | -$10.9K | 0.01% | 1348 |
|
|
2019
Q1 | $613K | Buy |
6,557
+221
| +3% | +$18.5K | 0.01% | 1162 |
|
|
2018
Q4 | $462K | Sell |
6,336
-19
| -0.3% | -$1.46K | 0.01% | 1242 |
|
|
2018
Q3 | $556K | Sell |
6,355
-147
| -2% | -$14.8K | 0.01% | 1284 |
|
|
2018
Q2 | $640K | Buy |
6,502
+514
| +9% | +$51K | 0.01% | 1153 |
|
|
2018
Q1 | $713K | Buy |
5,988
+84
| +1% | +$10.8K | 0.01% | 1069 |
|
|
2017
Q4 | $750K | Buy |
5,904
+352
| +6% | +$44.2K | 0.01% | 1038 |
|
|
2017
Q3 | $652K | Buy |
5,552
+600
| +12% | +$51.2K | ﹤0.01% | 1509 |
|
|
2017
Q2 | $395K | Buy |
4,952
+210
| +4% | +$13.4K | ﹤0.01% | 1873 |
|
|
2017
Q1 | $243K | Hold |
4,742
| – | – | ﹤0.01% | 2144 |
|
|
2016
Q4 | $178K | Sell |
4,742
-209
| -4% | -$8.75K | ﹤0.01% | 2417 |
|
|
2016
Q3 | $336K | Sell |
4,951
-226
| -4% | -$15.9K | ﹤0.01% | 1979 |
|
|
2016
Q2 | $287K | Buy |
5,177
+234
| +5% | +$14.7K | ﹤0.01% | 2086 |
|
|
2016
Q1 | $310K | Hold |
4,943
| – | – | ﹤0.01% | 1876 |
|
|
2015
Q4 | $465K | Buy |
4,943
+121
| +3% | +$11.2K | ﹤0.01% | 1663 |
|
|
2015
Q3 | $387K | Hold |
4,822
| – | – | ﹤0.01% | 1803 |
|
|
2015
Q2 | $578K | Buy |
4,822
+184
| +4% | +$22K | ﹤0.01% | 1644 |
|
|
2015
Q1 | $484K | Buy |
4,638
+361
| +8% | +$36.6K | ﹤0.01% | 1580 |
|
|
2014
Q4 | $415K | Buy |
4,277
+106
| +3% | +$9.82K | ﹤0.01% | 1903 |
|
|
2014
Q3 | $326K | Sell |
4,171
-21
| -0.5% | -$1.35K | ﹤0.01% | 2013 |
|
|
2014
Q2 | $265K | Sell |
4,192
-42,956
| -91% | -$2.55M | ﹤0.01% | 2305 |
|
|
2014
Q1 | $3.17M | Buy |
47,148
+898
| +2% | +$69.5K | 0.02% | 758 |
|
|
2013
Q4 | $2.98M | Buy |
46,250
+199
| +0.4% | +$11.9K | 0.02% | 770 |
|
|
2013
Q3 | $2.95M | Buy |
46,051
+526
| +1% | +$26.2K | 0.02% | 729 |
|
|
2013
Q2 | $1.41M | Buy |
+45,525
| New | +$1.21M | 0.01% | 1069 |
|
Other funds holding ALNY
Metropolitan Life Insurance Company (MetLife)'s ALNY Position: Q1 2022 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2022, closing a stake of 7,891 shares — an estimated $1.34M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in ALNY in Q2 2013 and held it in 35 quarters. The position peaked at $3.17M in Q1 2014. 444 funds tracked by Wall St. Rank hold ALNY as of Q1 2022.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Alnylam Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 7,891 Alnylam Pharmaceuticals shares in Q1 2022, an estimated $1.34M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 35 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Alnylam Pharmaceuticals position peaked at $3.17M in Q1 2014.
- 444 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2022.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.